SpaceX vs GeneDx Holdings Corp — how do they compare? SpaceX trades at $162.57 (market cap $2.18T), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: SpaceX is far larger — about 1079.2× GeneDx Holdings Corp's market cap, and SpaceX is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SpaceX for 41 Days and GeneDx Holdings Corp for 19 Days on average.
| SPCX | WGS | |
|---|---|---|
Market Cap | $2.18T | $2.02B |
Volume | 68,508,567 | 734,640 |
Sector | Industrials | Health |
52-Week High | $202.09 | $167.51 |
52-Week Low | $108.27 | $34.51 |
Typical Hold Time | 41 Days | 19 Days |
Enterprise Value | $2.12T | $2.05B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →